Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036096 | 0.90 | ALDH1A1 (0.49) | TSHRHRH3LMNAALDH1A1KDM4E | |
| SCHEMBL16695128 | 0.90 | ALDH1A1 (0.49) | TSHRHRH3LMNAALDH1A1KDM4E | |
| SCHEMBL28453533 | 0.89 | TSHR (0.46) | TSHRHRH3LMNAKDM4E | |
| SCHEMBL28442543 | 0.89 | TSHR (0.46) | TSHRHRH3LMNAKDM4E | |
| SCHEMBL1978680 | 0.85 | ALDH1A1 (0.44) | TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL13291086 | 0.84 | TSHR (0.53) | TSHRHRH3LMNAALDH1A1KDM4E | |
| SCHEMBL13905847 | 0.83 | TSHR (0.43) | TSHRHRH3ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL23293911 | 0.83 | ALDH1A1 (0.47) | TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL3331020 | 0.82 | HRH3 (0.43) | HRH3LMNA | |
| SCHEMBL6107526 | 0.82 | HRH3 (0.43) | HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843890-B | Application of triazolopyrimidine, triazolopyridine compound and composition thereof in treating PRC 2-mediated diseases | 中国科学院上海药物研究所 | 2022-03-29 | — | — | CN | disclosed |
| US-11013745-B2 | Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200261459-A1 | TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND THE COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-08-20 | — | — | US | disclosed |
| EP-3689875-A1 | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019062435-A1 | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | 中国科学院上海药物研究所 | 2019-04-04 | — | — | WO | disclosed |
| US-9636335-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-05-02 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-08 | — | — | US | disclosed |
| US-9079894-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LTD (IN) | 2015-07-14 | — | — | US | disclosed |
| EP-2758394-B1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-02-18 | — | — | EP | disclosed |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-07-03 | — | — | US | disclosed |
| EP-2513052-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2513052-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | TSHR 587/4885HRH3 201/4885LMNA 4722/4885 |
| US-20200261459-A1 | TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND THE COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | EED, EZH2, SUZ12 | TSHR 4355/4885HRH3 1426/4885LMNA 4378/4885 |
| US-11013745-B2 | Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases | EED, EZH2, SUZ12 | TSHR 4355/4885HRH3 1426/4885LMNA 4378/4885 |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | TSHR 200/4885HRH3 216/4885LMNA 4689/4885 |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | TSHR 200/4885HRH3 216/4885LMNA 4689/4885 |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | TSHR 587/4885HRH3 201/4885LMNA 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.